PDL BioPharma (PDLI) Tops Q1 EPS by 2c

PDL BioPharma (NASDAQ: PDLI) reported Q1 EPS of $0.52, $0.02 better than the analyst estimate of $0.50. Revenue for the quarter came in at $103.4 million versus the consensus estimate of $142.05 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Southside Bancshares (SBSI) Tops Q1 EPS by 1c
• Sanofi (SNY) Tops Q1 EPS by 85c; reaffirms guidance